PriceTargets.com logo

Shockwave Medical - SWAV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $309.11
  • Forecasted Upside: -6.33%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$330.00 As of 04/26/2024 01:00 AM ET
▲ +1.01 (0.31%)

This chart shows the closing price for SWAV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shockwave Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SWAV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SWAV

Analyst Price Target is $309.11
▼ -6.33% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Shockwave Medical in the last 3 months. The average price target is $309.11, with a high forecast of $368.00 and a low forecast of $210.00. The average price target represents a -6.33% upside from the last price of $330.00.

This chart shows the closing price for SWAV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Shockwave Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2024SVB LeerinkReiterated RatingOutperform ➝ Market Perform$361.00 ➝ $335.00Low
4/8/2024CL KingReiterated RatingBuy ➝ NeutralLow
4/8/2024Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Hold$270.00 ➝ $335.00Low
4/8/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$285.00 ➝ $335.00Low
4/5/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
4/5/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$263.00 ➝ $335.00Low
4/5/2024Needham & Company LLCReiterated RatingBuy ➝ HoldLow
4/5/2024Wolfe ResearchReiterated RatingOutperform ➝ Peer PerformLow
4/2/2024Piper SandlerBoost TargetOverweight ➝ Overweight$290.00 ➝ $360.00Low
3/27/2024CL KingInitiated CoverageBuy$368.00Low
2/16/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$200.00 ➝ $210.00Low
2/16/2024Piper SandlerBoost TargetOverweight ➝ Overweight$275.00 ➝ $290.00Low
2/16/2024Needham & Company LLCBoost TargetBuy ➝ Buy$260.00 ➝ $286.00Low
12/4/2023Morgan StanleyLower TargetOverweight ➝ Overweight$284.00 ➝ $223.00Low
11/7/2023Morgan StanleyLower TargetOverweight ➝ Overweight$313.00 ➝ $284.00Low
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$265.00 ➝ $260.00Low
10/24/2023Needham & Company LLCLower TargetBuy ➝ Buy$330.00 ➝ $265.00Low
10/16/2023Leerink PartnrsReiterated RatingOutperformLow
10/16/2023SVB LeerinkInitiated CoverageOutperform$263.00Low
9/29/2023UBS GroupInitiated CoverageNeutral$218.00Low
8/10/2023Morgan StanleyLower TargetOverweight ➝ Overweight$335.00 ➝ $313.00Low
8/8/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$275.00 ➝ $251.00Low
8/8/2023Needham & Company LLCBoost TargetBuy ➝ Buy$325.00 ➝ $330.00Low
7/10/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$291.00 ➝ $335.00Low
5/30/2023Morgan StanleyInitiated CoverageEqual Weight$291.00Low
5/9/2023VNET GroupReiterated RatingMaintainsLow
5/9/2023Deutsche Bank AktiengesellschaftBoost Target$285.00 ➝ $310.00Low
5/9/2023Needham & Company LLCBoost Target$283.00 ➝ $325.00Low
5/9/2023Piper SandlerBoost Target$280.00 ➝ $315.00Low
5/9/2023Wells Fargo & CompanyBoost Target$252.00 ➝ $275.00Low
4/11/2023Needham & Company LLCBoost TargetBuy$240.00 ➝ $283.00Low
4/11/2023Bank of AmericaBoost TargetBuy$235.00 ➝ $275.00Low
3/15/2023Needham & Company LLCInitiated CoverageBuy$240.00Low
2/17/2023Canaccord Genuity GroupBoost TargetBuy$247.00 ➝ $252.00Low
2/17/2023Wells Fargo & CompanyBoost TargetEqual Weight$200.00 ➝ $207.00Low
1/26/2023Piper SandlerLower TargetOverweight$300.00 ➝ $280.00Low
1/6/2023Morgan StanleyLower TargetEqual Weight$290.00 ➝ $224.00Low
12/16/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$285.00Low
12/12/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$300.00 ➝ $235.00Low
11/8/2022Wells Fargo & CompanyBoost TargetOverweight$255.00 ➝ $300.00Low
11/7/2022Bank of AmericaBoost Target$260.00 ➝ $310.00Low
10/11/2022Morgan StanleyBoost TargetEqual Weight$255.00 ➝ $290.00Low
9/6/2022OppenheimerDowngradeMarket Perform ➝ Underperform$165.00Low
8/29/2022Piper SandlerBoost TargetOverweight$278.00 ➝ $338.00Low
8/9/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$232.00 ➝ $256.00Low
8/9/2022Morgan StanleyBoost TargetEqual Weight$201.00 ➝ $255.00Low
8/9/2022Wells Fargo & CompanyBoost TargetOverweight$176.00 ➝ $255.00Low
8/9/2022Piper SandlerBoost TargetOverweight$245.00 ➝ $278.00Low
7/15/2022Morgan StanleyBoost TargetEqual Weight$180.00 ➝ $201.00Low
5/10/2022Canaccord Genuity GroupLower Target$221.00 ➝ $190.00High
5/10/2022Wells Fargo & CompanyLower Target$235.00 ➝ $176.00High
4/5/2022Wolfe ResearchInitiated CoverageOutperform$255.00Low
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyLow
2/18/2022Canaccord Genuity GroupLower Target$258.00 ➝ $198.00Medium
2/18/2022Morgan StanleyLower TargetEqual Weight$210.00 ➝ $199.00High
2/18/2022SVB LeerinkBoost TargetOutperform$160.00 ➝ $190.00High
2/18/2022Piper SandlerLower Target$272.00 ➝ $245.00High
1/7/2022Morgan StanleyBoost TargetEqual Weight$204.00 ➝ $210.00High
12/6/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$235.00High
11/9/2021Wells Fargo & CompanyBoost TargetEqual Weight$200.00 ➝ $235.00High
11/9/2021Piper SandlerBoost TargetOverweight$225.00 ➝ $272.00High
11/9/2021SVB LeerinkBoost TargetOutperform$250.00 ➝ $265.00High
8/10/2021Morgan StanleyBoost TargetEqual Weight$152.00 ➝ $200.00High
8/10/2021SVB LeerinkBoost TargetOutperform$208.00 ➝ $220.00High
7/15/2021SVB LeerinkInitiated CoverageOutperform$208.00High
7/12/2021Bank of AmericaDowngradeBuy ➝ Neutral$180.00 ➝ $200.00Low
6/18/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$189.00Medium
6/15/2021Piper SandlerBoost TargetOverweight$165.00 ➝ $207.00Medium
6/7/2021Wells Fargo & CompanyBoost TargetOverweight$161.00 ➝ $189.00High
5/11/2021Morgan StanleyBoost TargetEqual Weight$145.00 ➝ $152.00High
5/11/2021Wells Fargo & CompanyBoost TargetOverweight$151.00 ➝ $161.00High
5/11/2021Bank of AmericaUpgradeNeutral ➝ Buy$180.00High
5/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$134.00 ➝ $165.00High
4/28/2021OppenheimerReiterated RatingHoldHigh
4/19/2021Morgan StanleyBoost TargetEqual Weight$130.00 ➝ $145.00Low
2/25/2021Morgan StanleyBoost TargetEqual Weight$103.00 ➝ $130.00High
2/18/2021Piper SandlerBoost TargetNeutral$132.00 ➝ $134.00High
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$96.00 ➝ $132.00High
1/12/2021Wells Fargo & CompanyBoost TargetOverweight$95.00 ➝ $134.00High
12/15/2020Morgan StanleyBoost TargetEqual Weight$89.00 ➝ $103.00Low
12/1/2020Bank of AmericaDowngradeBuy ➝ Neutral$105.00High
11/11/2020Morgan StanleyBoost TargetEqual Weight$72.00 ➝ $89.00Low
11/10/2020Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $95.00High
11/10/2020Piper SandlerBoost TargetOverweight$86.00 ➝ $93.00High
10/19/2020Morgan StanleyBoost TargetEqual Weight$55.00 ➝ $72.00Medium
10/16/2020Wells Fargo & CompanyBoost TargetOverweight$80.00 ➝ $90.00High
10/16/2020Piper SandlerBoost TargetOverweight$76.00 ➝ $86.00High
9/18/2020Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$59.00 ➝ $80.00High
9/15/2020Piper SandlerBoost Target$58.00 ➝ $76.00Medium
8/12/2020Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $55.00High
8/12/2020Piper SandlerBoost TargetOverweight$54.00 ➝ $58.00High
7/8/2020OppenheimerInitiated CoverageHoldHigh
6/11/2020OppenheimerUpgradeUnderperform ➝ Market PerformHigh
6/9/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $54.00High
5/13/2020Morgan StanleyBoost TargetEqual Weight$40.00 ➝ $42.00High
5/13/2020Wells Fargo & CompanyBoost TargetBuy$43.00 ➝ $46.00High
5/12/2020OppenheimerInitiated CoverageSell$23.00High
4/21/2020Piper SandlerLower TargetOverweight$54.00 ➝ $45.00High
4/1/2020OppenheimerDowngradeMarket Perform ➝ Underperform$23.00High
3/27/2020Morgan StanleyLower TargetEqual Weight$51.00 ➝ $40.00Medium
2/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $50.00High
2/14/2020Piper SandlerBoost Target$50.00 ➝ $54.00Low
1/23/2020Piper SandlerReiterated RatingBuy$48.00Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$35.00 ➝ $47.00Low
12/12/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Overweight$49.00High
12/11/2019Piper Sandler CompaniesBoost TargetOverweight$43.00 ➝ $46.00High
11/8/2019Piper Sandler CompaniesBoost TargetOverweight$39.00 ➝ $43.00High
10/22/2019OppenheimerInitiated CoverageMarket PerformHigh
10/21/2019Piper Sandler CompaniesInitiated CoverageOverweight$39.00High
6/13/2019Bank of AmericaReiterated RatingNeutral$44.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 18 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 13 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 32 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 22 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 36 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 36 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Shockwave Medical logo
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $330.00
Low: $328.45
High: $330.28

50 Day Range

MA: $294.88
Low: $251.71
High: $330.00

52 Week Range

Now: $330.00
Low: $157.00
High: $331.58

Volume

530,986 shs

Average Volume

954,148 shs

Market Capitalization

$12.34 billion

P/E Ratio

85.27

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Shockwave Medical?

The following sell-side analysts have issued research reports on Shockwave Medical in the last twelve months: Canaccord Genuity Group Inc., CL King, Deutsche Bank Aktiengesellschaft, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Piper Sandler, SVB Leerink LLC, TheStreet, UBS Group AG, VNET Group, Inc., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for SWAV.

What is the current price target for Shockwave Medical?

9 Wall Street analysts have set twelve-month price targets for Shockwave Medical in the last year. Their average twelve-month price target is $309.11, suggesting a possible downside of 6.3%. CL King has the highest price target set, predicting SWAV will reach $368.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $210.00 for Shockwave Medical in the next year.
View the latest price targets for SWAV.

What is the current consensus analyst rating for Shockwave Medical?

Shockwave Medical currently has 10 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SWAV, but not buy more shares or sell existing shares.
View the latest ratings for SWAV.

What other companies compete with Shockwave Medical?

Other companies that are similar to Shockwave Medical include Insulet, NYSE:SOLV, Teleflex, Penumbra and Inspire Medical Systems. Learn More about companies similar to Shockwave Medical.

How do I contact Shockwave Medical's investor relations team?

Shockwave Medical's physical mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company's listed phone number is (877) 775-4846 and its investor relations email address is [email protected]. The official website for Shockwave Medical is www.shockwavemedical.com. Learn More about contacing Shockwave Medical investor relations.